Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Rating of “Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.00.

A number of equities research analysts have weighed in on AURA shares. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank lifted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright lifted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th.

Aura Biosciences Trading Down 1.4 %

Shares of AURA stock opened at $11.24 on Friday. Aura Biosciences has a 1 year low of $5.99 and a 1 year high of $12.38. The firm’s fifty day simple moving average is $8.93 and its 200 day simple moving average is $8.17. The firm has a market capitalization of $556.86 million, a P/E ratio of -6.04 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Equities research analysts anticipate that Aura Biosciences will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,506 shares of company stock worth $675,952. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new position in Aura Biosciences during the 3rd quarter worth about $169,000. Long Focus Capital Management LLC lifted its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after buying an additional 561,766 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after buying an additional 8,194 shares in the last quarter. Renaissance Technologies LLC lifted its position in Aura Biosciences by 26.3% during the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after buying an additional 15,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.